Market news

Viatris seeks court approval to launch generic Wegovy (semaglutide), challenging Novo Nordisk’s Orange Book patent. Read more here.

Investing.com -- Viatris filed a lawsuit against Novo Nordisk in Delaware federal court, requesting a determination that its planned generic version of Wegovy would not violate the Danish company's patent rights.

Oppenheimer rates Viatris and Teva Outperform with $25/$50 price targets. Read more here.

Viatris (VTRS) is facing multiple paths to earnings growth with an improving base business and a lat

Viatris (VTRS) has an average rating of overweight and mean price target of $19.67, according to ana

Viatris Inc. (NASDAQ:VTRS) announced on September 16 that Japan’s Ministry of Health, Labour and Welfare approved WAKIX, or pitolisant, for narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome in patients receiving treatment for airway obstruction. The narcolepsy approval covers types 1 and 2, with and without cataplexy, or sudden muscle weakness. The […]

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstruction, and approval for narcolepsy (type 1 and 2 – with and without cataplexy). WAKIX is the first histamine H3 receptor antagonist/inverse agonist approved in Japan fo

Viatris (VTRS) has an average rating of overweight and mean price target of $19, according to analys

Viatris (VTRS) has an average rating of overweight and mean price target of $18.71, according to ana

Viatris (VTRS) has an average rating of hold and mean price target of $18.71, according to analysts

Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.

Why recent generic drug earnings matter for Viatris stock Recent earnings across the generic drug industry highlighted steady demand alongside pricing and supply challenges, putting fresh attention on how Viatris (VTRS) is using new launches, product mix, and cost discipline to support its business. At a share price of US$16.34, Viatris has seen some short term pressure, with the 1 day share price return declining 3.26% and the 1 month share price return down 8.31%. However, the year to date...

Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential...

Viatris’ second-quarter results were met with a negative market reaction, despite the company surpassing Wall Street’s revenue and non-GAAP profit expectations. Management attributed the quarter’s performance to strong commercial execution in Greater China, where investments in established brands and e-commerce channels drove double-digit growth. CEO Scott Smith emphasized that demand for cardiovascular products and the company’s strategic focus on higher-margin generics in North America contrib

According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]

Detailed price information for Viatris Inc (VTRS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Viatris Inc (VTRS-Q) from The Globe and Mail including charting and trades.

Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.

Detailed price information for Viatris Inc (VTRS-Q) from The Globe and Mail including charting and trades.

Viatris Inc (VTRS) delivers 3.5% operational revenue growth and raises full-year 2026 guidance, while navigating supply disruptions and competitive pressures.